RIGL (Rigel Pharmaceuticals) NonCurrent Deferred Liabilities: $0.0 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

RIGL Rigel Pharmaceuticals Inc RIGL
75 GF Score
Price $41.70
GF Value $26.78
Valuation Significantly Overvalued
! 8 Warning Signs
View Full Analysis

What is Rigel Pharmaceuticals NonCurrent Deferred Liabilities?

Rigel Pharmaceuticals RIGL +3.71% 75 NonCurrent Deferred Liabilities is $0.0 Mil as of Jun. 2026. GuruFocus rates RIGL with a GF Score™ of 75/100 and a GF Value™ of $26.78 (Significantly Overvalued). The stock has 8 warning signs investors should review.

Non-Current Deferred Liabilities represents the non-current portion of obligations, which is a liability that usually would have been paid but is now pas due.

Rigel Pharmaceuticals's non-current deferred liabilities for the quarter that ended in Jun. 2026 was $0.0 Mil.

Rigel Pharmaceuticals NonCurrent Deferred Liabilities Related Terms

Rigel Pharmaceuticals NonCurrent Deferred Liabilities Historical Data

* Premium members only.

The historical data trend for Rigel Pharmaceuticals's NonCurrent Deferred Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Rigel Pharmaceuticals NonCurrent Deferred Liabilities Chart

Rigel Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
NonCurrent Deferred Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Rigel Pharmaceuticals Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
NonCurrent Deferred Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
RIGL
75GF Score
Rigel Pharmaceuticals Inc RIGL
NonCurrent Deferred Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a NonCurrent Deferred Liabilities of $0.0 Mil mean?
Rigel Pharmaceuticals (RIGL) has a NonCurrent Deferred Liabilities of $0.0 Mil as of Jun. 2026. Non-current deferred liabilities represent the company obligations not paid yet not due within the current period. View historical data on Rigel Pharmaceuticals and its competitors.
Is Rigel Pharmaceuticals' NonCurrent Deferred Liabilities too high?
Rigel Pharmaceuticals' current NonCurrent Deferred Liabilities is $0.0 Mil. Overall, Rigel Pharmaceuticals has a GF Score™ of 75/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Rigel Pharmaceuticals' NonCurrent Deferred Liabilities compare to SGP and OCS?
Rigel Pharmaceuticals' NonCurrent Deferred Liabilities of $0.0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good NonCurrent Deferred Liabilities for a Biotechnology company?
A good NonCurrent Deferred Liabilities depends on the Biotechnology industry context. However, NonCurrent Deferred Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high NonCurrent Deferred Liabilities mean?
A high NonCurrent Deferred Liabilities can signal that a stock is expensive relative to its fundamentals. Non-current deferred liabilities represent the company obligations not paid yet not due within the current period. View historical data on Rigel Pharmaceuticals and its competitors. Rigel Pharmaceuticals's current NonCurrent Deferred Liabilities is $0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rigel Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Rigel Pharmaceuticals (RIGL) is currently considered Significantly Overvalued. The stock's GF Value™ is $26.78, compared to a current price of $41.70 — trading 55.7% above its estimated fair value. The current NonCurrent Deferred Liabilities is $0.0 Mil. Rigel Pharmaceuticals' overall GF Score™ is 75/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is NonCurrent Deferred Liabilities calculated?
NonCurrent Deferred Liabilities is calculated from a company's financial statements. For Rigel Pharmaceuticals (RIGL), the current NonCurrent Deferred Liabilities is $0.0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Rigel Pharmaceuticals (RIGL) Overvalued in 2026?

Based on GuruFocus' analysis, Rigel Pharmaceuticals stock appears to be overvalued. The current stock price of $41.70 is trading 55.7% above its estimated GF Value™ of $26.78. GuruFocus considers Rigel Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for RIGL:

  • NonCurrent Deferred Liabilities: $0.0 Mil
  • GF Value™: $26.78 vs. price of $41.70 (55.7% above fair value)
  • GF Score™: 75/100 with 8 warning signs

No single metric tells the full story. See the RIGL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Rigel Pharmaceuticals Business Description

Other Exchanges RI2:Germany
Address 611 Gateway Boulevard, Suite 900, South San Francisco, CA, USA, 94080
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, REZLIDHIA (olutasidenib), GAVRETO (pralsetinib), R289, and Ocadusertib (Systemic) - Eli Lilly.
75GF Score

Get the complete analysis for RIGL

NonCurrent Deferred Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$41.70
Price
$26.78
GF Value